Subtopic Deep Dive
SLE Disease Activity Indices
Research Guide
What is SLE Disease Activity Indices?
SLE Disease Activity Indices are standardized scoring systems like SLEDAI, BILAG, and SRI used to quantify disease activity, monitor flares, and assess treatment responses in systemic lupus erythematosus patients.
Key indices include SLEDAI (Systemic Lupus Erythematosus Disease Activity Index), BILAG 2004 (British Isles Lupus Assessment Group), and SRI (SLE Responder Index). BILAG 2004 was developed and initially validated in a 2005 study by Isenberg et al. (614 citations). These tools standardize endpoints in clinical trials, with over 20 papers in the provided list referencing their use.
Why It Matters
SLE Disease Activity Indices enable consistent evaluation of treatment efficacy in trials, as shown in the anifrolumab study by Morand et al. (2019, 1206 citations) using composite endpoints including SRI. They support drug approvals like belimumab, validated via SRI in Furie et al. (2009, 465 citations). In practice, indices like BILAG 2004 (Isenberg et al., 2005) guide personalized monitoring and EULAR management recommendations (Fanouriakis et al., 2023).
Key Research Challenges
Index Responsiveness to Change
Detecting subtle improvements in low-activity states remains difficult for SLEDAI and BILAG. Isenberg et al. (2005) noted validation needs for BILAG 2004 responsiveness in real patients. Furie et al. (2009) developed SRI to address belimumab trial limitations in capturing response.
Optimal Cutoff Determination
Establishing precise cutoffs for remission or flare risks discordance across indices. Morand et al. (2019) used week-52 composite endpoints but highlighted variability versus prior trials. EULAR updates by Fanouriakis et al. (2023) emphasize standardized cutoffs for management.
Validation in Diverse Populations
Indices require testing across ethnicities for bias reduction. Somers et al. (2013, 432 citations) showed SLE prevalence variations in Michigan, underscoring population-specific validation needs. Vertsias et al. (2007) EULAR recommendations called for broader applicability.
Essential Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Eric F. Morand, Richard Furie, Yoshiya Tanaka et al. · 2019 · New England Journal of Medicine · 1.2K citations
Monthly administration of anifrolumab resulted in a higher percentage of patients with a response (as defined by a composite end point) at week 52 than did placebo, in contrast to the findings of a...
Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
Richard Furie, Munther A. Khamashta, Joan T. Merrill et al. · 2016 · Arthritis & Rheumatology · 827 citations
Objective To assess the efficacy and safety of anifrolumab, a type I interferon (IFN) receptor antagonist, in a phase IIb, randomized, double‐blind, placebo‐controlled study of adults with moderate...
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics
George Βertsias, John P. A. Ioannidis, J. Boletis et al. · 2007 · Annals of the Rheumatic Diseases · 751 citations
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Antonis Fanouriakis, Myrto Kostopoulou, Jeanette Andersen et al. · 2023 · Annals of the Rheumatic Diseases · 734 citations
BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus
David Isenberg, Anisur Rahman, Elizabeth Allen et al. · 2005 · Lara D. Veeken · 614 citations
Some significant changes in the BILAG disease activity index to assess patients with SLE are proposed. The process of demonstrating validity and reliability has started with these two exercises ass...
A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosus
Daniel J. Wallace, William Stohl, Richard Furie et al. · 2009 · Arthritis Care & Research · 586 citations
Abstract Objective To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combination with standard of care therapy (SOC) in patients with active systemic lupus erythem...
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
Munther A. Khamashta, Joan T. Merrill, Victoria P. Werth et al. · 2016 · Annals of the Rheumatic Diseases · 487 citations
NCT01283139; Results.
Reading Guide
Foundational Papers
Start with Isenberg et al. (2005) for BILAG 2004 development and validation, then Furie et al. (2009) for SRI from belimumab trials, as they establish core indices cited in 1000+ subsequent works.
Recent Advances
Study Morand et al. (2019) anifrolumab trial for SRI endpoint application (1206 citations) and Fanouriakis et al. (2023) EULAR update for current management using activity indices.
Core Methods
Core techniques: Weighted scoring (SLEDAI), organ-based alphabetic grading (BILAG), composite responder indices (SRI). Validation via trials assessing reliability, sensitivity to change, and discriminant validity.
How PapersFlow Helps You Research SLE Disease Activity Indices
Discover & Search
Research Agent uses searchPapers and citationGraph to map SLEDAI/BILAG/SRI literature from 250M+ OpenAlex papers, starting with Isenberg et al. (2005) BILAG 2004 (614 citations) as a hub. findSimilarPapers expands to validation studies; exaSearch queries 'SLEDAI responsiveness cutoffs' for trial endpoints like Morand et al. (2019).
Analyze & Verify
Analysis Agent applies readPaperContent to extract SRI definitions from Furie et al. (2009), then verifyResponse (CoVe) cross-checks claims against EULAR guidelines (Fanouriakis et al., 2023). runPythonAnalysis computes index correlations via pandas on trial data tables; GRADE grading scores evidence strength for BILAG responsiveness (Isenberg et al., 2005).
Synthesize & Write
Synthesis Agent detects gaps in cutoff validation across populations, flagging contradictions between SRI in belimumab (Wallace et al., 2009) and anifrolumab trials (Morand et al., 2019). Writing Agent uses latexEditText, latexSyncCitations for index comparison tables, latexCompile for reports, and exportMermaid for trial endpoint flowcharts.
Use Cases
"Compare SLEDAI vs BILAG responsiveness in recent trials using Python stats"
Research Agent → searchPapers('SLEDAI BILAG responsiveness') → Analysis Agent → readPaperContent(Isenberg 2005) + runPythonAnalysis(pandas correlation on trial scores) → statistical p-values and plots exported as CSV.
"Draft LaTeX review of SRI validation in biologic trials"
Synthesis Agent → gap detection(SRI belimumab anifrolumab) → Writing Agent → latexEditText(structured review) → latexSyncCitations(Furie 2009, Morand 2019) → latexCompile(PDF with tables).
"Find code for SLE disease activity index calculators from papers"
Research Agent → paperExtractUrls(SLEDAI implementations) → Code Discovery → paperFindGithubRepo → githubRepoInspect → verified Python scripts for index scoring.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ papers on BILAG/SRI, chaining citationGraph(Isenberg 2005) → DeepScan(7-step analysis with CoVe checkpoints on responsiveness data). Theorizer generates hypotheses on unified index cutoffs from EULAR updates (Fanouriakis 2023) and trial endpoints (Morand 2019).
Frequently Asked Questions
What is SLEDAI?
SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) scores 24 descriptors weighted 1-8 for active manifestations. It is widely used in trials like belimumab (Wallace et al., 2009). Limitations include poor flare detection addressed by SRI (Furie et al., 2009).
How was BILAG 2004 developed?
BILAG 2004 updated the alphabetic system for organ-based activity in SLE (Isenberg et al., 2005, 614 citations). Initial validation used real patient data across centers. It improves on prior versions for trial use.
What are key papers on SRI?
Furie et al. (2009, 465 citations) introduced SRI from belimumab phase II data, combining SLEDAI, no new BILAG A/B, and physician assessment. Used in anifrolumab trials (Morand et al., 2019). EULAR endorses it (Fanouriakis et al., 2023).
What are open problems in SLE indices?
Challenges include responsiveness in mild disease, population-specific cutoffs, and harmonization across SLEDAI/BILAG/SRI. Validation in diverse cohorts is needed (Somers et al., 2013). EULAR 2023 highlights endpoint standardization gaps.
Research Systemic Lupus Erythematosus Research with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching SLE Disease Activity Indices with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.